Prometheus Biosciences Long Term Debt

As of the most recent data (March 2023), RXDX shows a long-term debt of $26M. That compares with $14M in the prior-year period — up 89.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, RXDX's long-term debt is now $26M (was $14M) — a 89.2% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Prometheus Biosciences is outperforming or lagging.

Tracking RXDX's long-term debt over time shows whether Prometheus Biosciences is scaling, shrinking, or reshaping that part of the business. The current reading is $26M That compares with $14M in the prior-year period — up 89.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Prometheus Biosciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $26M) with ownership activity and broader fundamentals.

Prometheus Biosciences's long-term debt is $26M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.